Condition: Breast Cancer · Sponsor: Hellenic Cooperative Oncology Group
The present study will assess real-world clinical outcomes and adverse events from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive, HER2-negative advanced breast cancer.
This description comes directly from the study's public registry record.
Elena Fountzilas, MD, PhD · +306945779709 · FOUNTZILA@ONCOGENOME.GR
Areti Stamboliou · +302106912520 · a_stampoliou@hecog.ondsl.gr
Always discuss trial participation with your own doctor first.
| Hellenic Oncology Cooperative Group | Athens, Greece | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04985058